Here is the design of a clinical trial:

Official Title: Rehabkompassen® - a Novel Digital Tool for Facilitating Patient-tailored Rehabilitation in the Post-acute Continuum of Care After Stroke - A Multicenter Pragmatic Randomized Controlled Trial

Included conditions:
- Stroke

Study Armgroups:
- {'label': 'Intervention i.e. with Rehabkompassen®', 'type': 'EXPERIMENTAL', 'description': 'The participants will use the digital graphic Rehabkompassen® at follow-up.', 'interventionNames': ['Other: a usual follow-up with Rehabkompassen®']}
- {'label': 'Control exposure i.e. without Rehabkompassen®', 'type': 'ACTIVE_COMPARATOR', 'description': 'The participants will use Post-Stroke Checklist at follow-up as recommended by "Socialstyrelsen".', 'interventionNames': ['Other: a usual follow-up with Post-Stroke Checklist, i.e. without Rehabkompassen®']}

Interventions:
- {'type': 'OTHER', 'name': 'a usual follow-up with Rehabkompassen®', 'description': "Rehabkompassen® is a patient-centered digital graphic tool for capturing the patient's rehabilitation needs in the follow-up after stroke.", 'armGroupLabels': ['Intervention i.e. with Rehabkompassen®']}
- {'type': 'OTHER', 'name': 'a usual follow-up with Post-Stroke Checklist, i.e. without Rehabkompassen®', 'description': 'Post-Stroke Checklist consists of eleven questions concerning common and treatable post-stroke problems affecting quality of life.', 'armGroupLabels': ['Control exposure i.e. without Rehabkompassen®']}

Primary Outcomes:
- {'measure': 'Daily activities', 'description': 'The simplified modified Rankin Scale questionnaire (smRSq) will be used to measure daily activities and functional status. The smRSq is based on the yes/no responses to five questions, which in turn results an ordinal data of seven categories (0-6) of the modified Rankin Scale. A favorable outcome will be defined as mRS score of 0-2 (no symptoms to independent but with minor disability). A poor outcome will be defined as mRS score of 3-5 (disability but able to walk to bed-bound and in need of full nursing care) or 6 (death).', 'timeFrame': '12 months follow-up after stroke'}
- {'measure': 'Social activities', 'description': 'Stroke Impact Scale 3.0 (SIS)-participation (SIS-p) will be used to measure social activities. SIS-p is the dominant problem among persons after stroke reported in previous Swedish stroke RCTs; but not covered by smRSq. The SIS-p score ranges from 0-100 and the higher the score the less impact of stroke.', 'timeFrame': '12 months follow-up after stroke'}

Please estimate the sample size based on the assumption: 
90% power, significance level of 2.5% for each test, target familywise error rate of 5%, and a 15% loss to follow-up rate.
Sample size {14}
        The study is predicted to have 90% power in the analysis of both primary outcomes at a significance level of 2.5% for each individual test to account for planned correction for multiple comparisons with a target familywise error rate of 5%.
        Sample size calculations were performed assuming a mean difference of 4 points in the SIS-p score between the groups at the 12-month follow-up. There is uncertainty regarding the minimum clinically important difference in the SIS-p, but differences in sizes between 10 and 15 points have previously been suggested [29]. A power analysis was conducted using Monte Carlo simulations, in which SIS-p data for the control group were generated from a beta distribution with Î±â=â1.1 and Î²â=â0.5, while RehabkompassenÂ® data were generated under the assumption of Î±â=â1.1 and Î²â=â0.385. This corresponds approximately to a mean value of 70 and a standard deviation of 28 for the control group, in line with what Guidetti et al. [25] reported for a population of stroke patients at 12 months after stroke. Under these assumptions, the results showed that we need to include 940 patients to detect a statistically significant difference in the SIS-p score when using an ordinal proportional odds model to compare the groups at the 12-month follow-up. The average odds ratio across all simulations was 1.5, as estimated using the function orm from the R package rms for comparing the intervention group to the control group [40].
        The sample size calculation for the mRS score was based on aggregated unpublished data from the Swedish Stroke Register (Riksstroke). The marginal distribution of mRS scores collected 12Â months after stroke among Swedish patients was 0: 22.4%, 1: 18.0%, 2: 18.0%, 3: 16.8%, 4: 11.1%, 5: 4.3% and 6: 9.4%. The function popower from the package Hmisc [41] in the statistical software R was used to determine that a sample size of 940 patients (470 in each group) is sufficient to detect a true odds ratio of 0.67 at 90% power when using an ordinal proportional odds model to compare groups.
        Thus, 940 patients should be sufficient for both primary outcomes. To account for a 15% loss to follow-up rate, we plan to recruit 1106 patients for the study (Fig.Â 3).